| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5321 | Umc160 | Novel Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitor |
|
| DCC5322 | Um-c162 | Novel anti-virulence agent, rescuing nematodes from a Staphylococcus aureus infection and preventing the formation of biofilm in a dose-dependent manner without interfering with bacterial viability |
|
| DCC5323 | Unag Ligand | Novel fluorescent UnaG ligand, binding UnaG with high affinity (Kd = 3 nM) to induce a 2.5-fold fluorescence intensity enhancement and a 10 nm red shift |
|
| DCC5324 | Unbs3157 | Novel nonhematotoxic DNA intercalating agent with potent antitumor activity, inducing apoptosis via inhibition of key proteins in the PI3K/Akt/mTOR signaling pathway |
|
| DCC5325 | Unc0737 Featured | UNC0737 is a negative control of UNC0638 and the N-methyl analog of UNC0638. UNC0737 was designed to eliminate the hydrogen bond interaction seen in the G9a-UNC0224 cocrystal structure between Asp1083 of G9a and the secondary amino group at the 4-position of UNC0224's quinazoline ring3. UNC0737 was >300-fold less potent than UNC0638 in G9a and GLP biochemical assays. As expected, UNC0737 was a poor inhibitor of G9a (IC50 = 5,000 ± 200 nM (n = 2)) and GLP (IC50 > 10,000 nM (n = 2)) in the SAHH-coupled assays. |
|
| DCC5326 | Unc0965 | Biotinylated UNC0638, enabling chemiprecipitation of G9a from whole cell lysates |
|
| DCC5327 | Unc10112731 | Novel MYC protein stablizer, increasing the abundance of endogenous MYC proteintargeting the receptor tyrosine kinases KIT and platelet-derived growth factor receptor α (PDGFRα) |
|
| DCC5328 | Unc10112749a | Novel inhibitor of ROP18, inhibiting ROP18 within cells, and abrogating its effects on the host IRG pathway |
|
| DCC5329 | Unc10245092 | Novel Peptide Inhibitor for Calcium and Integrin Binding Protein 1 (CIB1) |
|
| DCC5330 | Unc1653 | Negative control for UNC1666 which is a dual Mer and Flt-3 tyrosine kinase inhibitor |
|
| DCC5331 | Unc32a | Orally Active Adenosine A 1 Receptor Agonist |
|
| DCC5332 | Unc4859 | Novel Ligand of EEDm acting as an allosteric inhibitor of PRC2 |
|
| DCC5333 | Unc5114 | Novel allosteric inhibitor of PRC2 catalytic activity |
|
| DCC5334 | Unc5115 | Novel allosteric inhibitor of PRC2 catalytic activity |
|
| DCC5335 | Unc5635 | Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT |
|
| DCC5336 | Unc5636 | Novel selective activator of PRC2-EED-I363M, showing minimal effects on the activity of PRC2-WT |
|
| DCC5337 | Unc6212 | Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|
| DCC5338 | Unc6349 | Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|
| DCC5339 | Unc6641 | Novel peptidomimetic antagonist of the PHF1 Tudor domain, binding both PHF1 Tudor domain and the related protein PHF19 |
|
| DCC5340 | Unc6864 | Novel inhibitor for histone methyllysine reader proteins (KmeRP), targeting CBX5 chromodomain |
|
| DCC5341 | Unc7040 | Novel potent and selective PAM of CBX8, blocking H3K27me3 binding and enhancing CBX8 affinity for nucleic acids, evicting PRC1 from H3K27me3 targets triggering DLBCL cell differentiation |
|
| DCC5342 | Unc9975 | Novel β-arrestin-biased D2 receptor (D2R) agonist |
|
| DCC5343 | Unipr500 Featured | Novel Eph antagonist, inhibiting Eph/ephrin interactions, enhancing glucose-stimulated insulin secretion (GSIS), and acting as a hypoglycemic agent |
|
| DCC5344 | Uodc14 | The first bifunctional (chemoreactive and clickable) probe for Adenosine A1 and A3 Receptors |
|
| DCC5345 | Upf-648 | Potent kynurenine 3-monooxygenase (kynurenine 3-hydroxylase; KMO) inhibitor |
|
| DCC5346 | Upg-100 | Novel superagonist of the urotensin-II (UT) receptor |
|
| DCC5347 | Upg-83 | Novel Potent antagonist of the Urotensin-II (UT) Receptor |
|
| DCC5348 | Upg-92 | Novel superagonist of the urotensin-II (UT) receptor |
|
| DCC5349 | Upg-95 | Novel potent antagonist of the Urotensin-II (UT) receptor |
|
| DCC5350 | Uproleselan | Novel E-Selectin antagonist, disrupting cell survival pathway activation, enhancing chemotherapy response and protecting from toxicity such as mucositis with improved survival in vivo |
|
